A practical treatment for COVID-19 and the next pandemic
Pharmacol Res Perspect
.
2022 Aug;10(4):e00988.
doi: 10.1002/prp2.988.
Authors
Jahar Bhattacharya
1
,
Robert Booy
2
,
Arturo Casadevall
3
,
Charles Dela Cruz
4
,
David S Fedson
5
,
Joe G N Garcia
6
,
Gary Grohmann
7
,
Ivan F N Hung
8
,
Jeffrey R Jacobson
9
,
Lance C Jennings
10
,
Lester Kobzik
11
,
Aleksandra Leligdowicz
12
,
James K Liao
13
,
Jennifer H Martin
14
,
Daniel M Musher
15
,
Charles N Serhan
16
,
Masato Tashiro
17
Affiliations
1
Department of Physiology & Cellular Biophysics, Vagelos Columbia College of Physicians & Surgeons, New York, New York, USA.
2
Department of Child and Adolescent Health, University of Sydney Medical School, Camperdown, New South Wales, Australia.
3
Department of Molecular Biology & Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
4
Department of Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
5
Sergy Haut, France.
6
Department of Medicine, University of Arizona College of Medicine, Tucson, Arizona, USA.
7
Director of Immunobiology, Therapeutic Goods Administration, Canberra, Australia.
8
Department of Medicine, University of Hong Kong, Pokfulam, Hong Kong.
9
Department of Medicine, University of Illinois College of Medicine-Chicago, Chicago, Illinois, USA.
10
Department of Pathology & Biomedical Science, University of Otago, Dunedin, New Zealand.
11
Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
12
Toronto General Research Institute, University of Toronto, Toronto, Canada.
13
Department of Medicine, University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA.
14
Discipline of Clinical Pharmacology, University of Newcastle School of Medicine and Public Health, Callaghan, New South Wales, Australia.
15
Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
16
Department of Anesthesiology, Perioperative & Pain Medicine, Mass General Brigham-Harvard Medical School, Boston, Massachusetts, USA.
17
National Institute of Infectious Diseases, Tokyo, Japan.
PMID:
35837790
PMCID:
PMC9284194
DOI:
10.1002/prp2.988
No abstract available
Keywords:
ACE inhibitors; ARBs; COVID-19; generic drugs; next pandemic; statins; treatment.
Publication types
Review
MeSH terms
Angiotensin Receptor Antagonists
COVID-19*
Humans
Pandemics*
SARS-CoV-2
Substances
Angiotensin Receptor Antagonists
Grants and funding
R01 HL136962/HL/NHLBI NIH HHS/United States